Search Result

Results for "

ethanolamides

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Biochemical Assay Reagents (3) Cannabinoid Receptor (12) COX (1) CXCR (2) Drug Derivative (3) Drug Intermediate (1) Drug Metabolite (1) Endogenous Metabolite (11) FAAH (1) Fluorescent Dye (1) GCGR (2) Interleukin Related (2) Isotope-Labeled Compounds (4) Leukotriene Receptor (1) Neuropeptide Y Receptor (3) Parasite (1) Phospholipase (1) Prostaglandin Receptor (3) TRP Channel (1)
By Research Areas:	Cancer (7) Endocrinology (1) Infection (1) Inflammation/Immunology (3) Metabolic Disease (13) Neurological Disease (14)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-124089S

*Eicosapentaenoyl ethanolamide-d4*	Isotope-Labeled Compounds Cannabinoid Receptor	Metabolic Disease
Eicosapentaenoyl ethanolamide-d₄ is the deuterium labeled Eicosapentaenoyl ethanolamide. Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is cannabinoid CB1/CB2 receptor agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant[1][2].

HY-171008

*Linoleoyl ethanolamide* phosphate**	Drug Intermediate	Metabolic Disease
Linoleoyl ethanolamide phosphate is an intermediate in the biosynthesis of Linoleoyl ethanolamide (HY-113421). Linoleoyl ethanolamide phosphate combined with other endogenous N-acylethanolamines plays a role in the regulation of food intake by selective prolongation of feeding latency and post-meal interval .

HY-112528

Glycerophospho-N-palmitoyl ethanolamine GP-NPEA	Endogenous Metabolite	Metabolic Disease
Glycerophospho-N-palmitoyl ethanolamine (GP-NPEA) is a metabolic precursor of palmitoyl ethanolamide PEA (HY-157829). Glycerophospho-N-palmitoyl ethanolamine decreases in the cortex of CUMS rats, which may be related to a disorder in the endocannabinoid system arising after the onset of depression .

HY-157829

(R)-Palmitoyl-(2-methyl)ethanolamide Me-PEA	Endogenous Metabolite	Cancer
(R)-Palmitoyl-(2-methyl)ethanolamide (Me-PEA) is a competitive inhibitor of [3 H]-AEA metabolism with a K_i value of 6.6 μM .

HY-113264S

*PGD2 ethanolamide-d4*	Isotope-Labeled Compounds	Others
PGD2 ethanolamide-d₄ is the deuterium labeled PGD2 ethanolamide[1].

HY-121996S

*Prostaglandin E2 ethanolamide-d4* PGE2 ethanolamide-d₄	Isotope-Labeled Compounds Others	Others
Prostaglandin E2 Ethanolamide-d4 (PGE2 ethanolamide-d4) is the deuterium labeled Prostaglandin E2 Ethanolamide (HY-121996) .

HY-113421S

*Linoleoyl ethanolamide-d4*	Isotope-Labeled Compounds Cannabinoid Receptor	Neurological Disease
Linoleoyl ethanolamide-d4 is a deuterated labeled Linoleoyl ethanolamide . Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .

HY-131651

Leukotriene B4 ethanolamide LTB4 ethanolamide	Endogenous Metabolite Leukotriene Receptor	Cancer
Leukotriene B4 ethanolamide (LTB4 ethanolamide) is an antagonist and a partial agonist for Leukotriene B4 (LTB4) receptor 1 (BLTR1). Leukotriene B4 ethanolamide ameliorates the tumor progression, which is only asscociated with inflammation .

HY-124089

Eicosapentaenoyl ethanolamide	Cannabinoid Receptor	Metabolic Disease
Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is cannabinoid CB1/CB2 receptor agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant .

HY-145475

Nervonoyl ethanolamide NEA	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
Nervonoyl ethanolamide (NEA) is an endogenous cannabinoid that can act as a presynaptic and postsynaptic neuromodulator. Nervonoyl ethanolamide can also be used in the research of inflammation .

HY-W721596

Pentadecanoyl ethanolamide	Endogenous Metabolite	Neurological Disease
Pentadecanoyl ethanolamide is derivate of endougenous lipid amides, the N-acylethanolamines. Pentadecanoyl ethanolamide exhibits anticonvulsant efficacy in electroshocked mice without significant toxicity .

HY-157833

Heptadecanoyl ethanolamide	Cannabinoid Receptor	Metabolic Disease
Heptadecanoyl ethanolamide is an endogenous cannabinoid. Heptadecanoyl ethanolamide is a synthetic analog of PEA which incorporates an odd-numbered (17-carbon) fatty acid chain .

HY-113516

20-HETE Ethanolamide	Endogenous Metabolite	Neurological Disease
20-HETE Ethanolamide is a metabolite of endocannabinoid Anandamide. 20-HETE Ethanolamide binds to the rat brain cannabinoid CB1 receptor with a K_i of 985 nM .

HY-169038

11(Z),14(Z)-Eicosadienoic acid ethanolamide	Cannabinoid Receptor Drug Derivative	Neurological Disease
11(Z),14(Z)-Eicosadienoic acid ethanolamide (Compound 3) is an ethanolamide-conjugated form of 11(Z),14(Z)-Eicosadienoic acid (HY-149589). 11(Z),14(Z)-Eicosadienoic acid ethanolamide inhibits the inactivating transport of an endogenous cannabinoid substance with an IC₅₀ value of 10.6 μM. 11(Z),14(Z)-Eicosadienoic acid ethanolamide can be used for research of neuropsychiatric conditions .

HY-113421

Linoleoyl ethanolamide Linoleic acid monoethanolamide	Cannabinoid Receptor	Neurological Disease
Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .

HY-165082

Tricosanoyl ethanolamide N-(2-Hydroxyethyl)-tricosanamide	Cannabinoid Receptor	Neurological Disease
Tricosanoyl ethanolamide is a member of endocannabinoids and its structure consists of ethanolamine and tricosanoic acid, which contains 23 carbon atoms. Tricosanoyl ethanolamide can be used for research of diseases related to the endocannabinoid system .

HY-130660

Prostaglandin F2α ethanolamide Prostamide F2α	Prostaglandin Receptor	Endocrinology
Prostaglandin F2α ethanolamide (Prostamide F2α) is an ethanolamide-like G protein-coupled receptor. Prostaglandin F2α is also a luteinizing hormone in sheep and may be a nociceptive mediator in the spinal cord .

HY-120968

Arachidoyl ethanolamide N-(2-Hydroxyethyl)-eicosanamide	Biochemical Assay Reagents	Metabolic Disease
Arachidoyl Ethanolamide (N-(2-hydroxyethyl)-eicosanamide) is an ester product.

HY-127061

Palmitoleoyl ethanolamide POEA	Endogenous Metabolite	Others
Palmitoleoyl ethanolamide (POEA) is an endogenous fatty amide with biological activity .

HY-119723

Myristoyl ethanolamide N-Myristoylethanolamine	Endogenous Metabolite	Others
Myristoyl ethanolamide (N-Myristoylethanolamine) is a class of N-acylserinol compounds .

HY-120969

Docosanoyl ethanolamide N-(2-Hydroxyethyl)-docosanamide	Biochemical Assay Reagents	Metabolic Disease
Docosanoyl Ethanolamide (N-(2-hydroxyethyl)-docosanamide) is an ester product.

HY-166206

(9Z,11E)-Octadecadien ethanolamide	Biochemical Assay Reagents	Metabolic Disease
(9Z,11E)-Octadecadien ethanolamide is an ester product.

HY-130357

15(S)-HETE Ethanolamide	Cannabinoid Receptor	Others
15(S)-HETE Ethanolamide is a cannabinoid analog the CB1 receptor (K_i of 600 nM) .

HY-W347540

oxy-Arachidonoyl ethanolamide O-alkyl-N-acylhydroxylamine	Endogenous Metabolite	Others
oxy-Arachidonoyl ethanolamide (O-alkyl-N-acylhydroxylamine) is an O-alkyl-N-acyl oxime derivative .

HY-121996

Prostaglandin E2 Ethanolamide PGE2 ethanolamide	Prostaglandin Receptor COX	Inflammation/Immunology
Prostaglandin E2 Ethanolamide (PGE₂-EA), an analog of PGE2, can be formed enzymatically following COX-2 oxygenation of endocannabinoids. Prostaglandin E2 Ethanolamide (PGE₂-EA) could modulate the production of the proinflammatory cytokine TNF-α in human blood and human monocytic cells .

HY-134615

Mead ethanolamide	Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
Mead ethanolamide is an endogenous cannabinoid receptor agonist with K_d values of 753 nM and 1810 nM against CB1 and CB2, respectively .

HY-113264

PGD2 ethanolamide	Apoptosis	Cancer
PGD2 ethanolamide is the COX-2 dependent metabolite of Anandamide that induces apoptosis in colorectal carcinoma (CRC) cells .

HY-W747573

N-Linolenoylethanolamine 18:3 NAE; α-Linolenoyl ethanolamide	TRP Channel	Neurological Disease
N-Linolenoylethanolamine (18:3 NAE) is an endocannabinoid. N-Linolenoylethanolamine is a vanillin receptor (TRPV1) agonist .

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a cannabinoid (CB) receptor agonist with K_is of 857 nM and 598 nM for human recombinant CB1 and CB2 receptors, respectively .

HY-134173

*Arachidonoyl ethanolamide* phosphate**	Cannabinoid Receptor Apoptosis	Neurological Disease
Arachidonoyl ethanolamide phosphate, an endocannabinoid, is an endogenous ligand for cannabinoid receptors in the central nervous system (CB1 subtype) and peripheral immune cells (CB2 subtype) .

HY-19636A

JNJ-42165279 dihydrochloride	FAAH	Others
JNJ-42165279 (dihydrochloride) is aFAAHinhibitor with IC₅₀ of 70 nM and 313 nM for hFAAH and rFAAH, respectively .

HY-138969

(±)10(11)-EDP ethanolamide 10,11-EDP-EA; 10,11-EDP epoxide; 10,11-Epoxy docosapentaenoic ethanolamide	Drug Derivative	Others
(±)10(11)-EDP ethanolamide (10,11-EDP-EA) (compound C) is an ω-3 endocannabinoid epoxide derivative with antiangiogenic, antitumor and anti-migratory properties in osteosarcoma models.

HY-165081

Docosaenoyl ethanolamide N-(2-Hydroxyethyl)-13Z-docosenamide	Others	Others
Docosaenoyl ethanolamide (N-(2-Hydroxyethyl)-13Z-docosenamide) is one of a fatty N-acyl ethanolamines. Ethanolamines can be detected at relatively high levels in rat cerebrospinal fluid .

HY-118816

11β-Prostaglandin F2α 11-epi PGF2α-EA; 11β-PGF2α-EA; 11β-Prostamide F2α	Drug Metabolite	Metabolic Disease
11β-Prostaglandin F2α ethanolamide (11β-PGF2α-EA) is the theoretical hepatic metabolite of PGD2-EA, produced during COX-2 metabolism of the endogenous cannabinoid AEA which is found in brain, liver, and other mammalian tissues.1 AEA can be used directly by COX-2 and specific PG synthase to produce ethanolamide congeners of the classical PGs. PGD2-EA is formed in activated RAW 264.7 cells treated with AEA.

HY-137567

Prostaglandin E1 ethanolamide	Prostaglandin Receptor	Cancer
Prostaglandin E1 ethanolamide is an analog of prostaglandin E1 (PGE1) and may effectively inhibit GLI2-induced expression of target genes, including Gli1 and Ptch1, and tumor growth .

HY-138971

(±)17(18)-EpETE-ethanolamide 17,18-EEQ-EA; (±)17,18-EEQ-ethanolamide; (±)17(18)-EpETE-EA	Interleukin Related	Others
(±)17(18)-EpETE-ethanolamide (17,18-EEQ-EA) (compound 17) is an ω-3 endocannabinoid epoxide with cytokine modulation in neuroinflammation studies, antiangiogenic effects in vascular endothelial cells, and vasodilatory effects on coronary arteries.

HY-138970

(±)19(20)-EDP ethanolamide 19,20-DHEA epoxide; 19,20-Epoxy docosapentaenoic acid ethanolamide; 19,20-EDP-EA	Interleukin Related	Others
(±)19(20)-EDP ethanolamide (19,20-DHEA epoxide) (compound 19) is an ω-3 endocannabinoid epoxide with cytokine modulation in neuroinflammation studies, antiangiogenic effects in vascular endothelial cells, and vasodilatory effects on coronary arteries.

HY-115358

Lignoceroyl Ethanolamide Tetracosanoic acid monoethanolamide	Endogenous Metabolite	Metabolic Disease
Lignoceroyl ethanolamide is a member of the family of fatty N-acyl ethanolamines collectively called endocannabinoids. Whereas lignoceric acid has been detected at relatively high levels in rat cerebrospinal fluid, the specific role and relative importance of its ethanolamine metabolite have not been determined.

HY-P4154

Bevonescein ALM-488	Fluorescent Dye	Neurological Disease Cancer
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .

HY-139247

pNPS-DHA	Drug Derivative	Inflammation/Immunology
pNPS-DHA (Compound 19) is an orally active DHA-ethanolamide (DHEA) derivative that has antiallergic activity. pNPS-DHA inhibits IgE-dependent passive cutaneous anaphylaxis (PCA) reaction in mice. pNPS-DHA has anti-degranulating activity in RBL-2H3 mast cells with an IC₅₀ of 15 μM .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P10026

Nisotirostide LY-3457263	Neuropeptide Y Receptor	Metabolic Disease
Nisotirotide (LY-3457263) is a PYY analog agonist studied in type 2 diabetes and obesity .

HY-P4757

N1-Glutathionyl-spermidine disulfide	Parasite	Others
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-112747

Soy PE LPI; PE (soy)	Phospholipase	Infection
Phosphatidylethanolamine is the most abundant phospholipid in prokaryotes and the second most abundant found in the membrane of mammalian, plant, and yeast cells, comprising approximately 25% of total mammalian phospholipids. In the brain, phosphatidylethanolamine comprises almost half of the total phospholipids. It is synthesized mainly through the cytidine diphosphate-ethanolamine and phosphatidylserine decarboxylation pathways, which occur in the endoplasmic reticulum (ER) and mitochondrial membranes, respectively. It is a precursor in the synthesis of phosphatidylcholine and arachidonoyl ethanolamide and is a source of ethanolamine used in various cellular functions. In E. coli, phosphatidylethanolamine deficiency prevents proper assembly of lactose permease, suggesting a role as a lipid chaperone. It is a cofactor in the propagation of prions in vitro and can convert recombinant mammalian proteins into infectious molecules even in the absence of RNA. This product contains phosphatidylethanolamine molecular species with variable fatty acyl chain lengths at the sn-1 and sn-2 positions.

Cat. No.	Product Name	Target	Research Area

HY-P4154

Bevonescein ALM-488	Fluorescent Dye	Neurological Disease Cancer
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P10026

Nisotirostide LY-3457263	Neuropeptide Y Receptor	Metabolic Disease
Nisotirotide (LY-3457263) is a PYY analog agonist studied in type 2 diabetes and obesity .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P4757

N1-Glutathionyl-spermidine disulfide	Parasite	Others
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113421

Linoleoyl ethanolamide Linoleic acid monoethanolamide	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Cannabinoid Receptor
Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .

HY-113516

20-HETE Ethanolamide	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
20-HETE Ethanolamide is a metabolite of endocannabinoid Anandamide. 20-HETE Ethanolamide binds to the rat brain cannabinoid CB1 receptor with a K_i of 985 nM .

HY-134615

Mead ethanolamide	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Cannabinoid Receptor Endogenous Metabolite
Mead ethanolamide is an endogenous cannabinoid receptor agonist with K_d values of 753 nM and 1810 nM against CB1 and CB2, respectively .

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Cannabinoid Receptor Endogenous Metabolite
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a cannabinoid (CB) receptor agonist with K_is of 857 nM and 598 nM for human recombinant CB1 and CB2 receptors, respectively .

Cat. No.	Product Name	Chemical Structure

HY-124089S

Eicosapentaenoyl ethanolamide-d4

Eicosapentaenoyl ethanolamide-d₄ is the deuterium labeled Eicosapentaenoyl ethanolamide. Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is cannabinoid CB1/CB2 receptor agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant[1][2].

HY-113264S

*PGD2 ethanolamide-d4*
PGD2 ethanolamide-d₄ is the deuterium labeled PGD2 ethanolamide[1].

HY-121996S

*Prostaglandin E2 ethanolamide-d4*
Prostaglandin E2 Ethanolamide-d4 (PGE2 ethanolamide-d4) is the deuterium labeled Prostaglandin E2 Ethanolamide (HY-121996) .

HY-113421S

Linoleoyl ethanolamide-d4

Linoleoyl ethanolamide-d4 is a deuterated labeled Linoleoyl ethanolamide . Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

ethanolamides

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products